Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BIO.B
stocks logo

BIO.B

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
0 Analyst Rating
down Image
Wall Street analysts forecast BIO.B stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO.B is USD with a low forecast of USD and a high forecast of  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
down Image
Current: 250.080
sliders
Low
Averages
High
down Image
Current: 250.080
sliders
Low
Averages
High
Wells Fargo
Brandon Couillard
Hold
Maintains
$320 → $270
2025-04-17
Reason
Wells Fargo
Brandon Couillard
Price Target
$320 → $270
2025-04-17
Maintains
Hold
Reason
Wells Fargo
Brandon Couillard
Hold
Maintains
$360 → $345
2025-02-12
Reason
Wells Fargo
Brandon Couillard
Price Target
$360 → $345
2025-02-12
Maintains
Hold
Reason
RBC Capital
Conor McNamara
Buy
Reiterates
$481
2025-01-14
Reason
RBC Capital
Conor McNamara
Price Target
$481
2025-01-14
Reiterates
Buy
Reason
RBC Capital
Conor McNamara
Buy
Maintains
$369 → $481
2024-12-09
Reason
RBC Capital
Conor McNamara
Price Target
$369 → $481
2024-12-09
Maintains
Buy
Reason
RBC Capital
Conor McNamara
Buy
Maintains
$446 → $469
2024-10-31
Reason
RBC Capital
Conor McNamara
Price Target
$446 → $469
2024-10-31
Maintains
Buy
Reason
Citigroup
Patrick Donnelly
Strong Buy
Maintains
$400 → $450
2024-10-31
Reason
Citigroup
Patrick Donnelly
Price Target
$400 → $450
2024-10-31
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bio Rad Laboratories Inc (BIO.B.N) is 28.58, compared to its 5-year average forward P/E of 28.69. For a more detailed relative valuation and DCF analysis to assess Bio Rad Laboratories Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
28.69
Current PE
28.58
Overvalued PE
31.05
Undervalued PE
26.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
17.11
Current EV/EBITDA
14.86
Overvalued EV/EBITDA
18.86
Undervalued EV/EBITDA
15.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
3.30
Current PS
2.61
Overvalued PS
3.73
Undervalued PS
2.87

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BIO.B News & Events

Events Timeline

(ET)
2025-07-07
09:23:59
Bio-Rad expands digital PCR offering with new platforms
select
2025-05-01 (ET)
2025-05-01
16:26:34
Bio-Rad now sees non-GAAP revenue for FY down 1% to up 1.5%
select
2025-05-01
16:26:08
Bio-Rad reports Q1 EPS $2.54, consensus $1.78
select
Sign Up For More Events
Sign Up For More Events

News

Preview
5.0
07-07Newsfilter
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

  • New Product Launch: Bio-Rad Laboratories has introduced four new Droplet Digital™ PCR platforms, including the QX Continuum™ and QX700™ series, enhancing their product portfolio for life science research and diagnostics with over 400,000 assays.

  • Market Impact: The new systems offer advanced capabilities such as high precision, multiplexing, and streamlined workflows, reinforcing Bio-Rad's leadership in digital PCR solutions across various applications including oncology and genetic research.

Preview
4.0
06-10Benzinga
5 Analysts Have This To Say About Bio-Rad Laboratories

  • Analyst Ratings Overview: Bio-Rad Laboratories has received mixed ratings from analysts, with recent evaluations showing a shift towards more bearish sentiments and a decrease in average price targets from $348.80 to $313.4 over the past three months.

  • Financial Performance Insights: Despite facing a decline in revenue growth of approximately 4.16%, Bio-Rad maintains strong financial metrics, including a net margin of 10.93% and a debt-to-equity ratio of 0.21, indicating effective cost management and lower reliance on debt financing.

Preview
1.0
05-30Newsfilter
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

  • Investor Meetings Announcement: Bio-Rad Laboratories' COO Jon DiVincenzo will hold one-on-one meetings with investors at the Jefferies Global Healthcare Conference in New York City on June 4, 2025.

  • Company Overview: Bio-Rad is a leading provider of life science research and clinical diagnostics products, generating $2.6 billion in revenue in 2024 and employing over 7,500 people globally.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bio Rad Laboratories Inc (BIO.B) stock price today?

The current price of BIO.B is 250.08 USD — it has increased 0 % in the last trading day.

arrow icon

What is Bio Rad Laboratories Inc (BIO.B)'s business?

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

arrow icon

What is the price predicton of BIO.B Stock?

Wall Street analysts forecast BIO.B stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO.B is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bio Rad Laboratories Inc (BIO.B)'s revenue for the last quarter?

Bio Rad Laboratories Inc revenue for the last quarter amounts to 585.40M USD, decreased -4.16 % YoY.

arrow icon

What is Bio Rad Laboratories Inc (BIO.B)'s earnings per share (EPS) for the last quarter?

Bio Rad Laboratories Inc. EPS for the last quarter amounts to 2.29 USD, decreased -82.97 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bio Rad Laboratories Inc (BIO.B)'s fundamentals?

The market is revising Downward the revenue expectations for Bio-Rad Laboratories, Inc. (BIO.B) for FY2025, with the revenue forecasts being adjusted by -1.69% over the past three months. During the same period, the stock price has changed by 3.34%.
arrow icon

How many employees does Bio Rad Laboratories Inc (BIO.B). have?

Bio Rad Laboratories Inc (BIO.B) has 7700 emplpoyees as of July 08 2025.

arrow icon

What is Bio Rad Laboratories Inc (BIO.B) market cap?

Today BIO.B has the market capitalization of 0.00 USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free